It seems Allergan has a more durable franchise in Restasis than some biotech investors would like to believe. A competitor to the dry eye drug from Eleven Biotherapeutics failed a Phase III pivotal trial, pushing the company to change focus.
Eleven Bio announced early 18 May that EBI-005 failed to reduce pain or damage to the cornea compared to a control in a 12-week study. Progress in the study was...
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
